Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444894 · ClinicalTrials.gov registry record · Phase 1
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
A Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia, sponsored by Editas Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 8
- Study locations
NCT05444894 is a Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia that is active but no longer recruiting, run by Editas Medicine. The registered enrollment target is 9 participants, below the 1,803-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05444894, a Phase 1 study of Hemoglobinopathies and Transfusion-dependent Beta-Thalassemia, is active but no longer recruiting, sponsored by Editas Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
Conditions Studied
Interventions
- GENETIC EDIT-301
Study Locations (8)
New York
- Columbia University Medical Center - Department of Pediatrics - New York
- Columbia University Medical Center - New York
California
- University of California San Francisco - Oakland
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers - Nashville
Ontario
- Princess Margaret Cancer Centre-University Health Network - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05444894
The ClinicalTrials.gov registry entry for NCT05444894 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,803-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (100% lower). The listed sponsor is Editas Medicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 1 intervention - of which EDIT-301 is the first listed.
NCT05444894 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05444894 about?
NCT05444894 is a clinical study titled "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)". The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia
What is the current status of trial NCT05444894?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-04-29. Estimated completion is 2025-12.
What conditions does trial NCT05444894 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Transfusion-dependent Beta-Thalassemia, Thalassemia Major, Thalassemia Intermedia.
What interventions are being tested in trial NCT05444894?
The interventions under investigation include: EDIT-301 (GENETIC).
Who is sponsoring clinical trial NCT05444894?
This trial is sponsored by Editas Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05444894 being conducted?
This trial has 8 study locations across California, Minnesota, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
ACTIVE NOT RECRUITING · Phase 1
-
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
COMPLETED · Phase 1
-
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
RECRUITING · NA
Explore more on PlainTrial
Hemoglobinopathies
All registered trials for this condition
Transfusion-dependent Beta-Thalassemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.